Best Practice & Research Clinical Rheumatology
Volume 20, Issue 5 , Pages 949-967 , October 2006

Spondyloarthropathy: disease at the crossroads of immunity

  • Oliver FitzGerald, MD FRCPI FRCP(UK) (Newman Clinical Research Professor)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +353 1 277 3721; Fax: +353 1 269 7949.

References 

  1. Baeten D, Kruithof E, De Rycke L, et al. Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Research and Therapy. 2005;7(2):R359–R369
  2. Ferrell WR, Lockhart JC, Kelso EB, et al. Essential role for proteinase-activated receptor-2 in arthritis. Journal of Clinical Investigation. 2003;111(1):35–41
  3. Akira S, Takeda K. Toll-like receptor signalling. Nature Reviews. Immunology. 2004;4(7):499–511
  4. Marshak-Rothstein A, Busconi L, Rifkin IR, Viglianti GA. The stimulation of Toll-like receptors by nuclear antigens: a link between apoptosis and autoimmunity. Rheumatic Diseases Clinics of North America. 2004;30(3):559–574ix
  5. Corr M. The tolls of arthritis. Arthritis and Rheumatism. 2005;52(8):2233–2236
  6. Radstake TR, van Lieshout AW, van Riel PL, et al. Dendritic cells, Fc{gamma} receptors, and toll-like receptors: potential allies in the battle against rheumatoid arthritis. Annals of the Rheumatic Diseases. 2005;64(11):1532–1538
  7. Roelofs MF, Joosten LA, Abdollahi-Roodsaz S, et al. The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis and Rheumatism. 2005;52(8):2313–2322
  8. Radstake TR, Roelofs MF, Jenniskens YM, et al. Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma. Arthritis and Rheumatism. 2004;50(12):3856–3865
  9. Seibl R, Birchler T, Loeliger S, et al. Expression and regulation of toll-like receptor 2 in rheumatoid arthritis synovium. American Journal of Pathology. 2003;162(4):1221–1227
  10. De Rycke L, Vandooren B, Kruithof E, et al. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of toll-like receptor 2 and toll-like receptor 4 in spondyloarthropathy. Arthritis and Rheumatism. 2005;52(7):2146–2158
  11. Raffeiner B, Dejaco C, Duftner C, et al. Between adaptive and innate immunity: TLR4-mediated perforin production by CD28null T-helper cells in ankylosing spondylitis. Arthritis Research and Therapy. 2005;7(6):R1412–R1420
  12. van der Paardt M, Crusius JB, de Koning MH, et al. No evidence for involvement of the toll-like receptor 4 (TLR4) A896G and CD14-C260T polymorphisms in susceptibility to ankylosing spondylitis. Annals of the Rheumatic Diseases. 2005;64(2):235–238
  13. Seta N, Granfors K, Sahly H, et al. Expression of host defense scavenger receptors in spondyloarthropathy. Arthritis and Rheumatism. 2001;44(4):931–939
  14. Yoshitomi H, Sakaguchi N, Kobayashi K, et al. A role for fungal {beta}-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice. Journal of Experimental Medicine. 2005;201(6):949–960
  15. Kop EN, Kwakkenbos MJ, Teske GJ, et al. Identification of the epidermal growth factor-TM7 receptor EMR2 and its ligand dermatan sulfate in rheumatoid synovial tissue. Arthritis and Rheumatism. 2005;52(2):442–450
  16. Lande R, Giacomini E, Serafini B, et al. Characterization and recruitment of plasmacytoid dendritic cells in synovial fluid and tissue of patients with chronic inflammatory arthritis. Journal of Immunology. 2004;173(4):2815–2824
  17. Cavanagh LL, Boyce A, Smith L, et al. Rheumatoid arthritis synovium contains plasmacytoid dendritic cells. Arthritis Research and Therapy. 2005;7(2):R230–R240
  18. Jongbloed SL, Lebre MC, Fraser AR, et al. Enumeration and pheotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis. Arthritis Research and Therapy. 2005;8(1):R15;[E-pub ahead of print]
  19. Danning CL, Illei GG, Hitchon C, et al. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis and Rheumatism. 2000;43(6):1244–1256
  20. Partsch G, Wagner E, Leeb BF, et al. T cell derived cytokines in psoriatic arthritis synovial fluids. Annals of the Rheumatic Diseases. 1998;57(11):691–693
  21. Kane D, Gogarty M, O'Leary J, et al. Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. Arthritis and Rheumatism. 2004;50(10):3286–3295
  22. Sfikakis PP, Kollias G. Tumor necrosis factor biology in experimental and clinical arthritis. Current Opinion in Rheumatology. 2003;15(4):380–386
  23. Van den Berg WB. Lessons from animal models of arthritis. Current Rheumatology Reports. 2002;4(3):232–239
  24. Ritchlin C, Haas-Smith SA, Hicks D, et al. Patterns of cytokine production in psoriatic synovium. Journal of Rheumatology. 1998;25(8):1544–1552
  25. Partsch G, Steiner G, Leeb BF, et al. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. Journal of Rheumatology. 1997;24(3):518–523
  26. Mease PJ, Antoni CE. Psoriatic arthritis treatment: biological response modifiers. Annals of the Rheumatic Diseases. 2005;64(supplement 2):ii78–ii82
  27. Goedkoop AY, Kraan MC, Teunissen MB, et al. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Annals of the Rheumatic Diseases. 2004;63(7):769–773
  28. McInnes IB, Gracie JA. Targeting cytokines beyond tumor necrosis factor-alpha and interleukin-1 in rheumatoid arthritis. Current Rheumatology Reports. 2004;6(5):336–342
  29. Tan AL, Marzo-Ortega H, O'Connor P, et al. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Annals of the Rheumatic Diseases. 2004;63(9):1041–1045
  30. Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Annals of the Rheumatic Diseases. 2005;64(2):296–298
  31. Rooney T, Murphy E, Benito M, et al. Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis. Annals of the Rheumatic Diseases. 2004;63(11):1393–1398
  32. Villadsen LS, Schuurman J, Beurskens F, et al. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. Journal of Clinical Investigation. 2003;112(10):1571–1580
  33. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. New England Journal of Medicine. 2004;351(20):2069–2079
  34. Kokkola R, Sundberg E, Ulfgren AK, et al. High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis and Rheumatism. 2002;46(10):2598–2603
  35. Foell D, Kane D, Bresnihan B, et al. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology (Oxford). 2003;42(11):1383–1389
  36. McInnes IB, Illei GG, Danning CL, et al. IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. Journal of Immunology. 2001;167(7):4075–4082
  37. Reece RC, Canete JD, Parsons WJ, et al. Distinct vascular patterns in the synovitis of psoriatic, reactive and rheumatoid arthritis. Arthritis and Rheumatism. 1999;42:1481–1485
  38. Korendowych E, Owen P, Ravindran J, et al. The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis. Rheumatology (Oxford). 2005;44(8):1056–1060
  39. Riente L, Chimenti D, Pratesi F, et al. Antibodies to tissue transglutaminase and Saccharomyces cerevisiae in ankylosing spondylitis and psoriatic arthritis. Journal of Rheumatology. 2004;31(5):920–924
  40. Cunnane G, Bresnihan B, FitzGerald O. Immunohistologic analysis of peripheral joint disease in ankylosing spondylitis. Arthritis and Rheumatism. 1998;41(1):180–182
  41. Laloux L, Voisin MC, Allain J, et al. Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Annals of the Rheumatic Diseases. 2001;60(4):316–321
  42. Veale DJ, Barnes L, Rogers S, FitzGerald O. Immunohistochemical markers for arthritis in psoriasis. Annals of the Rheumatic Diseases. 1994;53(7):450–454
  43. Mahmoud F, Abul H, al Saleh Q, et al. Elevated B-lymphocyte levels in lesional tissue of non-arthritic psoriasis. Journal of Dermatology. 1999;26(7):428–433
  44. Veale D, Yanni G, Rogers S, et al. Reduced synovial membrane ELAM-1 expression, macrophage numbers and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis and Rheumatism. 1993;36:893–900
  45. Costello P, Bresnihan B, O'Farrelly C, FitzGerald O. Predominance of CD8+ T lymphocytes in psoriatic arthritis. Journal of Rheumatology. 1999;26(5):1117–1124
  46. Costello PJ, Winchester RJ, Curran SA, et al. Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions that appear antigen driven. Journal of Immunology. 2001;166(4):2878–2886
  47. Curran SA, FitzGerald OM, Costello PJ, et al. Nucleotide sequencing of psoriatic arthritis tissue before and during methotrexate administration reveals a complex inflammatory T cell infiltrate with very few clones exhibiting features that suggest they drive the inflammatory process by recognizing autoantigens. Journal of Immunology. 2004;172(3):1935–1944
  48. Sieper J, Kingsley G, Palacios-Boix A, et al. Synovial T lymphocyte-specific immune response to Chlamydia trachomatis in Reiter's disease. Arthritis and Rheumatism. 1991;34(5):588–598
  49. Sieper J, Braun J, Wu P, Kingsley G. T cells are responsible for the enhanced synovial cellular immune response to triggering antigen in reactive arthritis. Clinical and Experimental Immunology. 1993;91(1):96–102
  50. Ackermann B, Staege MS, Reske-Kunz AB, et al. Enterobacteria-infected T cells as antigen-presenting cells for cytotoxic CD8 T cells: a contribution to the self-limitation of cellular immune reactions in reactive arthritis?. Journal of Infectious Diseases. 1997;175(5):1121–1127
  51. Kuon W, Lauster R, Bottcher U, et al. Recognition of chlamydial antigen by HLA-B27-restricted cytotoxic T cells in HLA-B*2705 transgenic CBA (H-2k) mice. Arthritis and Rheumatism. 1997;40(5):945–954
  52. Mertz AK, Wu P, Sturniolo T, et al. Multispecific CD4+ T cell response to a single 12-mer epitope of the immunodominant heat-shock protein 60 of Yersinia enterocolitica in Yersinia-triggered reactive arthritis: overlap with the B27-restricted CD8 epitope, functional properties, and epitope presentation by multiple DR alleles. Journal of Immunology. 2000;164(3):1529–1537
  53. Thiel A, Wu P, Lauster R, et al. Analysis of the antigen-specific T cell response in reactive arthritis by flow cytometry. Arthritis and Rheumatism. 2000;43(12):2834–2842
  54. Kuon W, Holzhutter HG, Appel H, et al. Identification of HLA-B27-restricted peptides from the Chlamydia trachomatis proteome with possible relevance to HLA-B27-associated diseases. Journal of Immunology. 2001;167(8):4738–4746
  55. Appel H, Kuon W, Kuhne M, et al. Use of HLA-B27 tetramers to identify low-frequency antigen-specific T cells in Chlamydia-triggered reactive arthritis. Arthritis Research and Therapy. 2004;6(6):R521–R534
  56. May E, Dulphy N, Frauendorf E, et al. Conserved TCR beta chain usage in reactive arthritis; evidence for selection by a putative HLA-B27-associated autoantigen. Tissue Antigens. 2002;60(4):299–308
  57. May E, Marker-Hermann E, Wittig BM, et al. Identical T-cell expansions in the colon mucosa and the synovium of a patient with enterogenic spondyloarthropathy. Gastroenterology. 2000;119(6):1745–1755
  58. Boyle LH, Goodall JC, Opat SS, Gaston JS. The recognition of HLA-B27 by human CD4(+) T lymphocytes. Journal of Immunology. 2001;167(5):2619–2624
  59. Goodall JC, Beacock-Sharp H, Deane KH, Gaston JS. Recognition of the 60 kilodalton cysteine-rich outer membrane protein OMP2 by CD4(+) T cells from humans infected with Chlamydia trachomatis. Clinical and Experimental Immunology. 2001;126(3):488–493
  60. Matyszak MK, Young JL, Gaston JS. Uptake and processing of Chlamydia trachomatis by human dendritic cells. European Journal of Immunology. 2002;32(3):742–751
  61. Boyle LH, Goodall JC, Gaston JS. Major histocompatibility complex class I-restricted alloreactive CD4+ T cells. Immunology. 2004;112(1):54–63
  62. Marker-Hermann E, Meyer zum Buschenfelde KH, Wildner G. HLA-B27-derived peptides as autoantigens for T lymphocytes in ankylosing spondylitis. Arthritis and Rheumatism. 1997;40(11):2047–2054
  63. Frauendorf E, von Goessel H, May E, Marker-Hermann E. HLA-B27-restricted T cells from patients with ankylosing spondylitis recognize peptides from B*2705 that are similar to bacteria-derived peptides. Clinical and Experimental Immunology. 2003;134(2):351–359
  64. Duchmann R, Lambert C, May E, et al. CD4+ and CD8+ clonal T cell expansions indicate a role of antigens in ankylosing spondylitis; a study in HLA-B27+ monozygotic twins. Clinical and Experimental Immunology. 2001;123(2):315–322
  65. Kuon W, Kuhne M, Busch DH, et al. Identification of novel human aggrecan T cell epitopes in HLA-B27 transgenic mice associated with spondyloarthropathy. Journal of Immunology. 2004;173(8):4859–4866
  66. Atagunduz P, Appel H, Kuon W, et al. HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis. Arthritis and Rheumatism. 2005;52(3):892–901
  67. Schon MP, Boehncke WH. Psoriasis. New England Journal of Medicine. 2005;352(18):1899–1912
  68. Piskin G, Koomen CW, Picavet D, et al. Ultraviolet-B irradiation decreases IFN-gamma and increases IL-4 expression in psoriatic lesional skin in situ and in cultured dermal T cells derived from these lesions. Experimental Dermatology. 2003;12(2):172–180
  69. Chang JC, Smith LR, Froning KJ, et al. CD8+ T cells in psoriatic lesions preferentially use T-cell receptor V beta 3 and/or V beta 13.1 genes. Proceedings of the National Academy of Sciences of the United States of America. 1994;91(20):9282–9286
  70. Tassiulas I, Duncan SR, Centola M, et al. Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Human Immunology. 1999;60(6):479–491
  71. Bos JD, de Rie MA, Teunissen MB, Piskin G. Psoriasis: dysregulation of innate immunity. British Journal of Dermatology. 2005;152(6):1098–1107
  72. Gottlieb SL, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Medicine. 1995;1:442–447
  73. Krueger GG. Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis. Journal of the European Academy of Dermatology and Venereology. 2003;17(supplement 2):17–24
  74. Feldman SR, Menter A, Koo JY. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. British Journal of Dermatology. 2004;150(2):317–326
  75. Gordon KB, Vaishnaw AK, O'Gorman J, et al. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Archives of Dermatology. 2003;139(12):1563–1570
  76. Kraan MC, van Kuijk AW, Dinant HJ, et al. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis and Rheumatism. 2002;46(10):2776–2784
  77. Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. Journal of the American Medical Association. 2003;290(23):3073–3080
  78. Zenz R, Eferl R, Kenner L, et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature. 2005;437(7057):369–375
  79. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis and Rheumatism. 2005;52(10):3279–3289
  80. Fraser AD, van Kuijk AWR, Westhovens R, et al. A randomized, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Annals of the Rheumatic Diseases. 2005;64(6):859–864

PII: S1521-6942(06)00081-7

doi: 10.1016/j.berh.2006.06.010

Best Practice & Research Clinical Rheumatology
Volume 20, Issue 5 , Pages 949-967 , October 2006

Article Tools

* Image Usage & Resolution